Company Overview and News

0
Unichem Laboratories Limited - Clarification

5h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UNICHEMLAB 506690

0
Will patent pact lift Unichem Labs?

2018-06-20 thehindubusinessline
Unichem Laboratories has entered into a settlement pact with pharma major Eli Lilly & Company and ICOS Corporation for resolving their patent litigation regarding generic tadalafil used for treating erectile dysfunction. Under the agreement, Unichem expects to launch its generic tadalafil product in the US on or not before March 26, 2019 under certain circumstances. It, however, did not provide any details about the ‘certain circumstances’.
UNICHEMLAB 506690

7
Unichem Laboratories rises 9% on settlement agreement with Eli Lilly

2018-06-20 moneycontrol
Shares of Unichem Laboratories added 9 percent intraday Wednesday as company entered in to settlement agreement with Eli Lilly.
UNICHEMLAB ICICIBANK 506690 532174 IBN

0
US FDA concludes inspection at Unichem Lab's Ghaziabad unit

2018-06-05 thehindubusinessline
Unichem Laboratories’ formulations manufacturing facility at Ghaziabad has received an Establishment Inspection Report from the US Food and Drug Administration, indicating closure of inspection. The inspection was conducted by the USFDA in April, the company said in a notice to the stock exchanges. Shares of Unichem Laboratories closed at ₹232.90, down 2.69 per cent, on the NSE.
UNICHEMLAB 506690

0
Unichem Laboratories Limited - Updates

2018-06-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UNICHEMLAB 506690

0
Unichem Laboratories hits 52-week low; receives EIR from USFDA for Ghaziabad unit

2018-06-05 moneycontrol
Shares of Unichem Laboratories touched 52-week low of Rs 233.30, down 3 percent intraday Tuesday as company received establishment inspection report (EIR) from United States Food and Drug Administration (USFDA).
UNICHEMLAB 506690

0
Unichem Laboratories Limited - AGM/Book Closure

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UNICHEMLAB 506690

0
Unichem Laboratories Limited - Dividend

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UNICHEMLAB 506690

0
Unichem Laboratories Limited - Outcome of Board Meeting

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UNICHEMLAB 506690

0
Unichem Laboratories Limited - Financial Result Updates

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UNICHEMLAB 506690

0
Unichem Laboratories Limited - Shareholders meeting

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UNICHEMLAB 506690

0
Unichem Laboratories Limited - Shareholders meeting

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UNICHEMLAB 506690

0
Unichem Laboratories advances 3% on ANDA approval for Valsartan tablets

2018-05-08 moneycontrol
Shares of Unichem Laboratories added 3.2 percent intraday Tuesday on the back of USFDA approval for Valsartan tablets.
UNICHEMLAB 506690

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...